Literature DB >> 33568096

Clinical utility of complex assessment with evoked potentials in acute lymphoblastic leukemia survivors: comparison of various treatment protocols.

Slawomir Kroczka1,2, Konrad Stepien3,4, Izabela Witek-Motyl2, Kinga Kwiecinska3,4, Eryk Kapusta2, Agnieszka Biedron2, Pawel Skorek3,4, Szymon Skoczen5,6.   

Abstract

BACKGROUND: One of the greatest success of pediatric hematology is a prominent improvement of survival in acute lymphoblastic leukemia (ALL). Therefore, special attention needs to be paid to long-term side effects of the treatment such as neurotoxicity. One of the few diagnostic methods that allow an objective assessment of sensory systems are evoked potentials (EP).
METHODS: The analyzed group consisted of 167 ALL long-term survivors, aged 4.9-28.4 years, without auditory, visual and sensory deviations. Patients were treated with New York (NY, n = 35), previous modified Berlin-Frankfurt-Münster (pBFM, n = 47) and BFM95 (n = 85) protocols. In order to assess the impact of radiotherapy on recorded EP, a joint analysis of NY and pBFM groups was performed. The control group consisted of 35 patients, aged 6-17 years. The analyzed patients underwent a complex assessment with visual EP (VEP), somatosensory EP (SEP) and brainstem auditory EP (BAEP) in accordance with current standards.
RESULTS: ALL treatment contributed to the shortening of wave I latency (1.59 vs 1.90, P = 0.003) and prolongation of I-III (2.23 vs 2.04, P = 0.004) and I-V (4.57 vs 4.24, P = 0.002) interwave latencies of BAEP. A significant effect was also noticed in P100 (106.32 vs 101.57, P < 0.001) and N135 (151.42 vs 138.22, P < 0.001) latencies of VEP and N18 amplitude (3.24 vs 4.70, P = 0.007) and P25 latency (21.32 vs 23.39, P < 0.001) of SEP. The distribution of abnormalities between protocols was similar in BAEP (NY - 68.6%, pBFM - 61.7%, BFM95-69.4%, P = 0.650), VEP (NY - 68.6%, pBFM - 42.5%, BFM95-58.3%, P = 0.053) and significantly different for SEP (NY - 62.9%, pBFM - 36.2%, BFM95-53.0%, P = 0.045). The harmful effect of radiotherapy was most clearly marked in numerous disturbances of SEP parameters.
CONCLUSIONS: The presented analysis indicates a high frequency of subclinical abnormalities in EP regardless of the analyzed protocol. To our knowledge current study is the largest and one of the most complex research examining the role of EP in ALL patients. The obtained results indicate the possibility of using a single, objective and non-invasive measurement of EP in ALL survivors in order to stratify the risk of developing sensory abnormalities in adulthood.

Entities:  

Keywords:  Acute lymphoblastic leukemia; Children; Evoked potentials; Radiotherapy; Survivors

Mesh:

Year:  2021        PMID: 33568096      PMCID: PMC7876796          DOI: 10.1186/s12885-021-07873-x

Source DB:  PubMed          Journal:  BMC Cancer        ISSN: 1471-2407            Impact factor:   4.430


  25 in total

1.  Neurotoxicity of BFM-95 on the medial olivocochlear bundle assessed by means of contralateral suppression of 2f1-f2 distortion product otoacoustic emissions.

Authors:  Maria Riga; Stavros Korres; Ioannis Psarommatis; Maria Varvutsi; Ioannis Giotakis; Theodoros Papadas; Eleftherios Ferekidis; Nikolaos Apostolopoulos
Journal:  Otol Neurotol       Date:  2007-02       Impact factor: 2.311

2.  Diabetes mellitus in long-term survivors of childhood cancer. Increased risk associated with radiation therapy: a report for the childhood cancer survivor study.

Authors:  Lillian R Meacham; Charles A Sklar; Suwen Li; Qi Liu; Nora Gimpel; Yutaka Yasui; John A Whitton; Marilyn Stovall; Leslie L Robison; Kevin C Oeffinger
Journal:  Arch Intern Med       Date:  2009-08-10

3.  Acute profound sensorineural hearing loss as the initial manifestation of acute leukemia--report of a case.

Authors:  T Harada; S Namiki; I Kawabata
Journal:  Auris Nasus Larynx       Date:  2000-10       Impact factor: 1.863

4.  Childhood leukemia survivors exhibit deficiencies in sensory and cognitive processes, as reflected by event-related brain potentials after completion of curative chemotherapy: A preliminary investigation.

Authors:  Kelin M Brace; Wei Wei Lee; Peter D Cole; Elyse S Sussman
Journal:  J Clin Exp Neuropsychol       Date:  2019-06-03       Impact factor: 2.475

5.  Visual-evoked potentials in long-term survivors of acute lymphoblastic leukemia in childhood. The German Late Effects Working Group.

Authors:  M A Uberall; H Hertzberg; W Meier; T Langer; J D Beck; D Wenzel
Journal:  Neuropediatrics       Date:  1996-08       Impact factor: 1.947

6.  Nervous system assessment with evoked potential tests in pediatric bone marrow transplant patients.

Authors:  T A Kaleita; W D Shields; S A Feig; M R Nuwer
Journal:  Am J Pediatr Hematol Oncol       Date:  1984

7.  Blood Pressure Status in Adult Survivors of Childhood Cancer: A Report from the St. Jude Lifetime Cohort Study.

Authors:  Todd M Gibson; Zhenghong Li; Daniel M Green; Gregory T Armstrong; Daniel A Mulrooney; DeoKumar Srivastava; Nickhill Bhakta; Kirsten K Ness; Melissa M Hudson; Leslie L Robison
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2017-11-22       Impact factor: 4.254

8.  [Auditory evoked potentials in patients after acute children's lymphoblastic leukemia treatment].

Authors:  Slawomir Kroczka; Małgorzata Steczkowska-Klucznik; Agata Romaniszyn
Journal:  Przegl Lek       Date:  2006

9.  International incidence of childhood cancer, 2001-10: a population-based registry study.

Authors:  Eva Steliarova-Foucher; Murielle Colombet; Lynn A G Ries; Florencia Moreno; Anastasia Dolya; Freddie Bray; Peter Hesseling; Hee Young Shin; Charles A Stiller
Journal:  Lancet Oncol       Date:  2017-04-11       Impact factor: 41.316

10.  Genetic Signature of Acute Lymphoblastic Leukemia and Netherton Syndrome Co-incidence-First Report in the Literature.

Authors:  Szymon Skoczen; Konrad Stepien; Wojciech Mlynarski; Piotr Centkowski; Kinga Kwiecinska; Michal Korostynski; Marcin Piechota; Elzbieta Wyrobek; Angelina Moryl-Bujakowska; Wojciech Strojny; Magdalena Rej; Jerzy Kowalczyk; Walentyna Balwierz
Journal:  Front Oncol       Date:  2020-01-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.